| ||||||||
| | | | 1 | | | ||
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 7 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | | A-1 | | |
Name | | | Age | | | Position with the Company | | | Director Since | |
Class I Director – Term expires 2020 | | | | | | | | | | |
James J. McGorry | | | 61 | | | CEO and Director | | | 2013 | |
James Shmerling, DHA, FACHE(1) | | | 63 | | | Director | | | 2018 | |
Class II Directors – Nominated to Serve a Term Expiring 2021 | | | | | | | | | | |
John J. Canepa*(1)(3) | | | 62 | | | Director | | | 2013 | |
Wei Zhang, MD, Ph.D.* | | | 46 | | | Director Nominee | | | N/A | |
Class II Director – Term expires 2018 | | | | | | | | | | |
Thomas H. Robinson(2)(3) | | | 59 | | | Director | | | 2012 | |
Class III Directors – Term expires 2019 | | | | | | | | | | |
Jason Jing Chen | | | 56 | | | Chairman | | | 2018 | |
Blaine H. McKee, Ph.D.(1) | | | 53 | | | Director | | | 2016 | |
Director Name | | | Age | | | Position with the Company | | | Since | |
Class I Director – Term expires 2020; Nominated to Serve a Term Expiring 2023 | | | | | | | | | | |
James Shmerling,* DHA, FACHE(1)(2)(3) | | | 65 | | | Director | | | 2018 | |
Class II Directors – Term expires 2021 | | | | | | | | | | |
Ting Li | | | 43 | | | Director | | | 2018 | |
Jeffrey Young(1) | | | 47 | | | Director | | | 2018 | |
Wei Zhang, MD, Ph.D.(2)(3) | | | 48 | | | Director | | | 2018 | |
Class III Director – Term expires 2023 | | | | | | | | | | |
Jason Jing Chen | | | 58 | | | Chairman | | | 2018 | |
Name and Principal Position | | Year | | Salary | | Stock Awards(1) | | Option Awards(2) | | All Other Compensation | | Total | | | Year | | Salary | | Stock Awards(1) | | Option Awards(2) | | All Other Compensation | | Total | | ||||||||||||||||||||||||||||||||||||||||||||||||
James McGorry Chief Executive Officer | | | | | 2017 | | | | $ | 338,942 | | | | $ | 50,688 | | | | $ | 71,931 | | | | $ | 15,920(3) | | | | $ | 477,481 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2016 | | | | $ | 375,000 | | | | | — | | | | $ | 168,720 | | | | $ | 19,208(4) | | | | $ | 562,928 | | | ||||||||||||||||||||||||||||||||||||||||||||
Thomas McNaughton Chief Financial Officer | | | | | 2017 | | | | $ | 279,289 | | | | $ | 28,512 | | | | $ | 40,461 | | | | $ | 15,202(5) | | | | $ | 363,464 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2016 | | | | $ | 309,000 | | | | | — | | | | $ | 84,360 | | | | $ | 16,721(6) | | | | $ | 410,081 | | | ||||||||||||||||||||||||||||||||||||||||||||
Saverio LaFrancesca, M.D. Former President and Chief Medical Officer | | | | | 2017 | | | | $ | 321,529 | | | | $ | 41,183 | | | | $ | 58,444 | | | | $ | 1,000(7) | | | | $ | 422,156 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2016 | | | | $ | 400,000 | | | | | — | | | | $ | 84,360 | | | | $ | 1,238(8) | | | | $ | 485,598 | | | ||||||||||||||||||||||||||||||||||||||||||||
James McGorry Former Chief Executive Officer) | | | | | 2019 | | | | $ | 375,000 | | | | | — | | | | | — | | | | $ | 20,651(3) | | | | $ | 395,651 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | $ | 411,058 | | | | | — | | | | $ | 699,694 | | | | $ | 9,545(4) | | | | $ | 1,120,297 | | | ||||||||||||||||||||||||||||||||||||||||||||
William Fodor, PhD Chief Scientific Officer | | | | | 2019 | | | | $ | 305,000 | | | | | — | | | | | — | | | | $ | 17,151(5) | | | | $ | 322,151 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | $ | 140,769 | | | | | — | | | | $ | 847,713 | | | | $ | 4,396(6) | | | | $ | 992,878 | | | ||||||||||||||||||||||||||||||||||||||||||||
Thomas McNaughton(9) Former Chief Financial Officer) | | | | | 2019 | | | | $ | 235,498 | | | | | — | | | | $ | 61,982 | | | | $ | 8,531(7) | | | | $ | 306,011 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | $ | 338,712 | | | | | — | | | | $ | 427,592 | | | | $ | 14,916(8) | | | | $ | 781,220 | | | ||||||||||||||||||||||||||||||||||||||||||||
Hong Yu President | | | | | 2019 | | | | $ | 150,000 | | | | | — | | | | | — | | | | $ | 7,950(10) | | | | $ | 157,950 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | $ | 88,269 | | | | | — | | | | $ | 427,592 | | | | $ | 2,849(11) | | | | $ | 518,710 | | | ||||||||||||||||||||||||||||||||||||||||||||
Peter Chakoutis Vice President of Finance | | | | | 2019 | | | | $ | 181,923 | | | | | — | | | | $ | 57,492 | | | | $ | 9,896(12) | | | | $ | 249,311 | | | ||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | $ | 119,000 | | | | | — | | | | $ | 75,583 | | | | $ | 4,773(13) | | | | $ | 199,356 | | |
Name | | | Fees earned or paid in cash | | | Stock awards(1)(2) | | | Option awards(1)(3) | | | Total | | ||||||||||||
John J. Canepa | | | | $ | 30,000 | | | | | $ | 7,008 | | | | | $ | 6,338 | | | | | $ | 43,346 | | |
John F. Kennedy(4) | | | | $ | 30,000 | | | | | $ | 7,008 | | | | | $ | 6,338 | | | | | $ | 43,346 | | |
Blaine H. McKee | | | | $ | 30,000 | | | | | $ | 7,008 | | | | | $ | 6,338 | | | | | $ | 43,346 | | |
Thomas H. Robinson | | | | $ | 30,000 | | | | | $ | 7,008 | | | | | $ | 6,338 | | | | | $ | 43,346 | | |
Name | | | Fees earned or paid in cash | | | Option awards(1)(2) | | | Total | | |||||||||
Jason Jing Chen | | | | $ | 0 | | | | | $ | 62,914 | | | | | $ | 62,914 | | |
Matthew Dallas | | | | $ | 0 | | | | | $ | 44,998 | | | | | $ | 44,998 | | |
Ting Li | | | | $ | 0 | | | | | $ | 48,010 | | | | | $ | 48,010 | | |
James Shmerling, DHA FACHE | | | | $ | 0 | | | | | $ | 44,998 | | | | | $ | 44,998 | | |
Jeffrey Young | | | | $ | 0 | | | | | $ | 44,998 | | | | | $ | 44,998 | | |
Wei Zhang MD, Ph.D | | | | $ | 0 | | | | | $ | 57,160 | | | | | $ | 57,160 | | |
| | Option Awards | | Restricted Stock Unit Awards | | | Option Awards | | Restricted Stock Units | | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Securities Underlying Restricted Stock Units | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | Option Exercise Price ($) | | Option Expiration Date | | Number of Securities Underlying Restricted Stock Units | | ||||||||||||||||||||||||||||||||||||||||
James McGorry | | | | 1,250 | | | | | — | | | | $ | 85.80 | | | | | 11/18/2023 | | | | | — | | | | | | | 1,250 | | | | | — | | | | $ | 85.80 | | | | | 11/18/2023 | | | | | — | | | |||||||||
| | | | 1,250 | | | | | — | | | | $ | 36.80 | | | | | 5/29/2025 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 16,785 | | | | | 16,785(1) | | | | $ | 27.60 | | | | | 7/6/2025 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 1,875 | | | | | 5,625(2) | | | | $ | 33.80 | | | | | 3/22/2026 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 13,400(3) | | | | $ | 7.68 | | | | | 3/14/2027 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,600(4) | | | ||||||||||||||||||||||||||||||||||||
Thomas McNaughton | | | | 277 | | | | | — | | | | $ | 58.00 | | | | | 11/14/2018 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 555 | | | | | — | | | | $ | 65.40 | | | | | 5/21/2019 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 138 | | | | | — | | | | $ | 115.80 | | | | | 6/2/2021 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 219 | | | | | | | | | $ | 73.40 | | | | | 6/1/2022 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 103 | | | | | — | | | | $ | 104.40 | | | | | 5/31/2023 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | — | | | | | — | | | | | — | | | | | — | | | | | 13(5) | | | ||||||||||||||||||||||||||||||||||||
| | | | 2,418 | | | | | 1,209(6) | | | | $ | 85.80 | | | | | 11/18/2023 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 7,256 | | | | | — | | | | $ | 85.80 | | | | | 11/18/2023 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 2,125 | | | | | 2,125(7) | | | | $ | 36.80 | | | | | 5/29/2025 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 2,500 | | | | | 2,500(8) | | | | $ | 28.00 | | | | | 8/31/2025 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | 937 | | | | | 2,812(2) | | | | $ | 33.80 | | | | | 3/22/2026 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 7,537(3) | | | | $ | 7.68 | | | | | 3/14/2027 | | | | | — | | | ||||||||||||||||||||||||||||||||||||
| | | | — | | | | | — | | | | | — | | | | | — | | | | | 3,712(4) | | | ||||||||||||||||||||||||||||||||||||
James McGorry | | | | | 1,250 | | | | | — | | | | $ | 36.80 | | | | | 5/29/2025 | | | | | — | | | |||||||||||||||||||||||||||||||||||
| | | 33,570 | | | | | — | | | | $ | 27.60 | | | | | 7/6/2025 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 5,625 | | | | | 1,875(1) | | | | $ | 33.80 | | | | | 3/22/2026 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 6,700 | | | | | 6,700(2) | | | | $ | 7.68 | | | | | 3/14/2027 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 85,616 | | | | | 85,616(3) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | 34,247 | | | | | 136,987(4) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | 3,300(5) | | | |||||||||||||||||||||||||||||||||||||
| | | 52,322 | | | | | 52,321(3) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
William Fodor, Ph.D | | | | | 20,929 | | | | | 83,714(4) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||
| | | 52,322 | | | | | 52,321(3) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
Hong Yu | | | | | 20,929 | | | | | 83,714(4) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||
| | | 19,026 | | | | | 19,026(6) | | | | $ | 2.72 | | | | | 5/29/2028 | | | | | — | | | |||||||||||||||||||||||||||||||||||||
Peter Chakoutis | | | | | 2,500 | | | | | 27,500(7) | | | | $ | 2.29 | | | | | 8/8/2029 | | | | | — | | |
| | | Shares Beneficially Owned by Title or Class of Securities | | | ||||||||||||||||||||
| | | Common Stock | | | Series D Preferred | | | |||||||||||||||||
Name and Address of Beneficial Owner(1) | | | Shares | | | Percent(2) | | | Shares | | | Percent(3) | | | |||||||||||
Greater than 5% Holders | | | | | | | | | | | | | | | | | | | | | | | | | |
Jinhui Liu | | | | | 368,318 | | | | 8.3%(4) | | | | | | | | | | | | | | | | |
DST Capital LLC and Affiliates | | | | | 4,365,722 | | | | 49.99%(5) | | | | | 3,000 | | | | | | 96.53% | | | | | |
Hong Yu | | | | | 300,000 | | | | 6.4%(6) | | | | | | | | | | | | | | | | |
Shunfu Hu | | | | | 240,000 | | | | 5.2%(7) | | | | | | | | | | | | | | | | |
Named Executive Officers | | | | | | | | | | | | | | | | | | | | | | | | | |
James J. McGorry | | | | | 42,742 | | | | 1.0%(8) | | | | | | | | | | | | | | | | |
Thomas W. McNaughton | | | | | 31,643 | | | | 0.7%(9) | | | | | | | | | | | | | | | | |
Non-Employee Directors | | | | | | | | | | | | | | | | | | | | | | | | | |
John J. Canepa | | | | | 6,774 | | | | *(10) | | | | | | | | | | | | | | | | |
Jason Jing Chen | | | | | 210,000 | | | | 4.6%(11) | | | | | 54 | | | | | | 1.74% | | | | | |
Blaine H. McKee | | | | | 4,662 | | | | *(12) | | | | | | | | | | | | | | | | |
Thomas H. Robinson | | | | | 8,412 | | | | *(13) | | | | | | | | | | | | | | | | |
James Shmerling | | | | | — | | | | — | | | | | | | | | | | | | | | | |
All current executive officers and directors, as a group (7 persons) | | | | | 304,233 | | | | 6.5%(14) | | | | | | | | | | | | | | | | |
Director Nominee | | | | | | | | | | | | | | | | | | | | | | | | | |
Wei Zhang | | | | | — | | | | — | | | | | | | | | | | | | | | | |
| | | Common Stock Beneficially Owned | | |||||||||
Name and Address of Beneficial Owner(1) | | | Shares | | | Percent(2) | | ||||||
Greater than 5% Holder | | | | | | | | | | | | | |
DST Capital LLC and Affiliates | | | | | 3,237,722 | | | | | | 37.0%(3) | | |
Du Xiaoyu | | | | | 750,000 | | | | | | 8.8%(4) | | |
Zhou Heping | | | | | 500,000 | | | | | | 5.9%(5) | | |
Named Executive Officers | | | | | | | | | | | | | |
Hong Yu | | | | | 417,771 | | | | | | 4.7%(6) | | |
William Fodor, Ph.D | | | | | 73,251 | | | | | | *%(7) | | |
Peter Chakoutis | | | | | 19,795 | | | | | | *%(8) | | |
Non-employee Directors | | | | | | | | | | | | | |
Jason Jing Chen | | | | | 247,226 | | | | | | 2.8%(9) | | |
Ting Li | | | | | 30,942 | | | | | | *%(10) | | |
James Shmerling, DHA FACHE | | | | | 29,672 | | | | | | *%(11) | | |
Jeffrey Young | | | | | 54,672 | | | | | | *%(12) | | |
Wei Zhang MD, Ph.D | | | | | 34,800 | | | | | | *%(13) | | |
All current executive officers and directors, as a group (8 persons) | | | | | 908,129 | | | | | | 9.7%(14) | | |
Plan Category | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units, Warrants and Rights | | Weighted Average Exercise Price of Outstanding Options, Warrants, and Rights | | Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) | | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units, Warrants and Rights | | Weighted Average Exercise Price of Outstanding Options, Warrants, and Rights | | Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) | | ||||||||||||||||||||||||
| | (a) | | (b) | | (c) | | | (a) | | (b) | | (c) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders(1) | | | | 182,349 | | | | $ | 42.10 | | | | | 311,803(2) | | | | | | 1,776,061 | | | | | 6.03 | | | | | 308,357(2) | | | ||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | | | | ||||||
Total | | | | 182,349 | | | | $ | 42.10 | | | | | 311,803 | | | | | | 1,776,061 | | | | | 6.03 | | | | | 308,357 | | |
| | 2019 | | 2018 | | |||||||||||||||||||||||||||||||||
| | 2016 | | 2017 | | | RSM | | RSM | | KPMG | | Total | | ||||||||||||||||||||||||
Audit Fees(1) | | | $ | 546,575 | | | | $ | 251,220 | | | | | $ | 212,625 | | | | $ | 189,000 | | | | $ | 71,000 | | | | $ | 260,000 | | | ||||||
Tax Fees(2) | | | $ | 13,000 | | | | $ | 15,000 | | | | | | 16,065 | | | | | 18,161 | | | | | — | | | | | 18,161 | | | ||||||
All Other Fees(3) | | | $ | 1,650 | | | | $ | 1,780 | | | |||||||||||||||||||||||||||
Total Fees | | | $ | 561,225 | | | | $ | 268,000 | | | | | $ | 228,690 | | | | $ | 207,161 | | | | $ | 71,000 | | | | $ | 278,161 | | |
| | | Number of Stock Options Awards | | | Number of Restricted Stock Units Awards | | | Number of Shares Underlying All Awards | | |||||||||
James McGorry – Chief Executive Officer | | | | | 13,400 | | | | | | 6,600 | | | | | | 20,000 | | |
Thomas McNaughton – Chief Financial Officer | | | | | 7,537 | | | | | | 3,712 | | | | | | 11,249 | | |
Saverio LaFrancesca – Former Chief Medical Officer | | | | | 10,887 | | | | | | 5,362 | | | | | | 16,249 | | |
All executive officers as a group | | | | | 31,824 | | | | | | 15,674 | | | | | | 47,498 | | |
All directors who are not executive officers, as a group | | | | | 5,000 | | | | | | 3,648 | | | | | | 8,648 | | |
Employees as a group (excluding executive officers) | | | | | 55,500 | | | | | | — | | | | | | 55,500 | | |
Total | | | | | 92,324 | | | | | | 19,322 | | | | | | 111,646 | | |
|